Plain English Summary
Background and study aims
Smoking is a major cause of ill health including lung disease, health disease and cancer. It is important that the NHS makes use of the best approaches to help people to stop smoking. People with a history of smoking are now being offered screening by CT scan in order to detect early lung cancer so these can be treated and cured. This screening program is also an opportunity to help people to quit smoking. The usual approach would be to direct individuals to NHS or local authority smoking cessation services. The aim of this study is to see if a more intense approach, where smokers can see a smoking cessation counsellor immediately, is more effective.
Who can participate?
Smokers aged 50 to 65 who wish to quit who are going through the screening programme
What does the study involve?
Participants are randomly allocated to receive either immediate smoking cessation input including pharmacotherapy (drug treatment) or usual care, which is advice and signposting to local services. Smoking rates are compared 3 months later.
What are the possible benefits and risks of participating?
The intervention may increase the likelihood of quitting smoking.
Where is the study run from?
Royal Brompton and Harefield NHS Foundation Trust (UK)
When is the study starting and how long is it expected to run for?
February 2018 to May 2022 (updated 01/12/2020, previously: April 2019)
Who is funding the study?
Royal Marsden Partners (UK)
Who is the main contact?
1. Dr Nicholas Hopkinson
2. Dr Ahmad Sadaka
Dr Nicholas Hopkinson
Royal Brompton Hospital Campus
+44 (0)20 7351 8029
Dr Ahmad Sadaka
Royal Brompton Hospital
IRAS 236191; CPMS 39463
QuLIT – the Quit smoking Lung health Intervention Trial
In people who smoke attending a lung cancer CT screening programme, does the provision of immediate smoking cessation support including pharmacotherapy compared to signposting to a smoking cessation service improve quit rates at 3 months?
Approved 30/04/2018, South Central - Oxford C Research Ethics Committee (Level 3, Block B, Whitefriars Building, Lewins Mead, Bristol, BS1 2NT; Tel: +44 (0)20 7104 8049; Email: email@example.com), REC ref:18/SC/0236
Randomised; Interventional; Design type: Treatment, Screening, Drug, Education or Self-Management, Imaging, Psychological & Behavioural, Complex Intervention
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
A study comparing the effectiveness of two different smoking cessation strategies applied in a pseudo-randomised fashion. Smokers attending a lung health screening service, focussed on CT screening to detect early lung cancer, will receive either:
1. Immediate smoking cessation input including pharmacotherapy
2. Usual care, which will be advice and signposting to local services
Limited resources mean that a specialist smoking cessation practitioner will only be available on 5 days every fortnight so treatment allocation will depend on this (i.e., which day patients attend on).
Follow up will be by phone call at 3 months.
Primary outcome measure
Quit rate in those wishing to quit, based on self-report by telephone call at 3 months following the initial screening visit
Secondary outcome measures
1. Quit rate in all screening program participants, based on self-report by telephone call at 3 months following the initial screening visit
2. Mortality at 1 year (available as part of the routine evaluation of the screening protocol)
1. The impact of the smoking cessation interventions (based on self-report by telephone call at three months) in different baseline groups including:
1.1. Those with new abnormal findings found as part of screening (e.g. spirometry)
1.2. Those with or without an abnormal CT finding that requires further follow up
2. The number of individuals who are smoking and who wish to quit will also be documented to provide guidance for service development and resource requirements
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Participant in the clinical lung health screening programme (aged 50 to 65 and any history of smoking)
2. Current smoker
3. Only those who express a wish to quit smoking will be included in the primary endpoint analysis
Target number of participants
Participant exclusion criteria
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Royal Brompton and Harefield NHS Foundation Trust
Royal Marsden Partners
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer-reviewed journal by the end of 2021.
IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.
Intention to publish date
Participant level data
To be made available at a later date
Basic results (scientific)
- ISRCTN12455871_PROTOCOL_28Feb18.pdf Uploaded 01/07/2019